ExodusPoint Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

ExodusPoint Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,964	Closed	-$81K	–	2664
2022 Q1	$81K	Buy	+11,964	New	+$85.3K	﹤0.01%	2027
2021 Q3	–	Sell	-26,064	Closed	-$177K	–	2832
2021 Q2	$177K	Buy	26,064 +15,189	+140%	+$126K	﹤0.01%	2024
2021 Q1	$112K	Buy	+10,875	New	+$119K	﹤0.01%	1969
2020 Q3	–	Sell	-13,738	Closed	-$95K	–	2360
2020 Q2	$95K	Buy	+13,738	New	+$74.1K	﹤0.01%	1639
2020 Q1	–	Sell	-10,100	Closed	-$88K	–	1789
2019 Q4	$88K	Buy	+10,100	New	+$54.6K	﹤0.01%	1437

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

ExodusPoint Capital Management's JNCE Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 11,964 shares — an estimated $81K sold.

ExodusPoint Capital Management first reported a position in JNCE in Q4 2019 and held it in 5 quarters. The position peaked at $177K in Q2 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

ExodusPoint Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
ExodusPoint Capital Management sold 11,964 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $81K.
ExodusPoint Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
ExodusPoint Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $177K in Q2 2021.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.